Dr. Paul Auwaerter discusses the BA.2 Subvariant and the recent authorization from the FDA for second booster dose. Topics: *Virulence of BA.2 vs Omicron and Delta * Therapeutic activity of monoclonal antibodies against BA.2 *Details of approval for booster #2 (4th and 5th dose) *Are there advantages to mixing mRNA vaccines? 


Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/3-30-22-episode/eval  


Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty 


Presenting faculty:  

Paul G. Auwaerter, MD, MBA, FIDSA, Past President of the Infectious Diseases Society of America (IDSA), Professor of Medicine, Johns Hopkins University School of Medicine 


See acast.com/privacy for privacy and opt-out information.